Marshall Wace
KZR

Marshall Wace’s Kezar Life Sciences KZR Stock Holding History

Marshall Wace’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,968
Closed -$61.6K – 2729
2023
Q1 		$61.6K Buy
1,968
+693
+54% +$40.1K ﹤0.01% 2529
2022
Q4 		$89.8K Sell
1,275
-64,569
-98% -$4.79M ﹤0.01% 2801
2022
Q3 		$5.67M Sell
65,844
-125,008
-65% -$12.1M 0.01% 1286
2022
Q2 		$15.8M Buy
190,852
+145,302
+319% +$12.8M 0.03% 585
2022
Q1 		$7.57M Buy
+45,550
New +$6.54M 0.01% 1073
2020
Q4 		– Sell
-4,320
Closed -$209K – 2041
2020
Q3 		$209K Sell
4,320
-3,865
-47% -$185K ﹤0.01% 1450
2020
Q2 		$423K Buy
+8,185
New +$413K ﹤0.01% 1246
2019
Q4 		– Sell
-3,252
Closed -$107K – 1907
2019
Q3 		$107K Sell
3,252
-2,050
-39% -$99K ﹤0.01% 1389
2019
Q2 		$409K Buy
5,302
+1,336
+34% +$208K ﹤0.01% 1125
2019
Q1 		$704K Buy
+3,966
New +$782K 0.01% 1038

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Marshall Wace's KZR Position: Q2 2023 in Review

Marshall Wace sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 1,968 shares — an estimated $61.6K sold.

Marshall Wace first reported a position in KZR in Q1 2019 and held it in 10 quarters. The position peaked at $15.8M in Q2 2022. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

  • Marshall Wace reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
  • Marshall Wace sold 1,968 Kezar Life Sciences shares in Q2 2023, an estimated $61.6K.
  • Marshall Wace first reported a position in Kezar Life Sciences in Q1 2019 and held it in 10 quarters.
  • Marshall Wace's Kezar Life Sciences position peaked at $15.8M in Q2 2022.
  • 104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on Marshall Wace's 13F filing for Q2 2023, filed 14 Aug 2023.